Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Drug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

Fineline Cube May 20, 2026
Company Drug

Hengrui and Braveheart Bio Report Positive Phase 2 Results for Next-Gen Cardiac Myosin Inhibitor HRS-1893 in Non-Obstructive HCM

Fineline Cube May 12, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and Braveheart Bio announced positive results...

Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026

Akari Therapeutics (NASDAQ: AKTX), the US-UK dual-headquartered biotechnology company, announced a strategic development partnership with...

Policy / Regulatory

NMPA Releases 105th Batch of Generic Drug Reference Standards, Adding 37 New Specifications

Fineline Cube May 12, 2026

China’s National Medical Products Administration (NMPA) announced the release of the 105th batch of reference...

Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026

China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based...

Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026

Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the...

Company Deals

Hybio Pharmaceutical Expands Torrent Pharma Partnership with Lanreotide Acetate for U.S. Market

Fineline Cube May 12, 2026

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced an expanded strategic partnership with Torrent Pharmaceuticals Inc.,...

Company Deals

Hybio Pharmaceutical Licenses GLP-1 Copycats to MCG Pharma for Exclusive Turkish Commercialization

Fineline Cube May 12, 2026

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced a strategic licensing agreement with MCG Pharma, the...

Company Deals

Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh

Fineline Cube May 12, 2026

Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the...

Others

Cue Biopharma Licenses Ascendant-221 Anti-IgE Antibody for $691.5M Deal, Excluding Greater China

Fineline Cube May 12, 2026

Cue Biopharma Inc. (NASDAQ: CUE) announced an exclusive licensing agreement with Ascendant Health Sciences Ltd.,...

Company Deals

Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties

Fineline Cube May 12, 2026

Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology...

Company Deals

Beijing Sun-Novo Partners with Chinese Academy of Medical Sciences on Category 1 Antibacterial Drug IMB0304

Fineline Cube May 12, 2026

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced a strategic research and development partnership...

Company Drug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

Fineline Cube May 12, 2026

CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received a second Breakthrough Therapy Designation...

Company Drug

AmoyDx PCR11 Companion Diagnostic Approved in Japan for Johnson & Johnson’s Rybrevant in NSCLC with EGFR Exon 20 Insertions

Fineline Cube May 12, 2026

Amoy Diagnostics Co., Ltd. (SHE: 300685) announced in collaboration with Japanese partners Riken Genesis Co.,...

Company Drug

CanSino Biologics’ Five-Component Pertussis Vaccine Enters NMPA Priority Review for Ages 6+

Fineline Cube May 12, 2026

CanSino Biologics Inc. (HKG: 6185) announced that China’s National Medical Products Administration (NMPA) has included...

Others

GSK Partners with Sino Biopharmaceutical’s CTTQ Subsidiary to Commercialize Bepirovirsen in China’s Hepatitis B Market

Fineline Cube May 11, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai...

Company Deals

Starna Therapeutics Closes $40M Series B+ Round to Advance In Vivo CAR-T and Extrahepatic mRNA Delivery Platforms

Fineline Cube May 11, 2026

Starna Therapeutics, a clinical-stage mRNA drug developer based in Suzhou, announced the completion of a...

Company Drug

Henlius Biotech Expands European Footprint with Two Additional EC Approvals for HanSiZhuang PD-1 Inhibitor

Fineline Cube May 11, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has secured two additional indication approvals from...

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance...

Medical Device

MicroPort CardioFlow Secures CE Mark for ENO Series Pacemakers with Advanced LBBAP Capability

Fineline Cube May 11, 2026

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of MicroPort Scientific Corp (HKG: 0853),...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives Fifth NMPA Breakthrough Therapy Designation for Esophageal Cancer

Fineline Cube May 11, 2026

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its B7-H3-targeted antibody-drug conjugate (ADC) HS-20093...

Posts pagination

1 … 5 6 7 … 669

Recent updates

  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
  • Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets
  • Shanghai ZJ Bio-Tech Secures International Approvals for Molecular Diagnostic Platforms in Netherlands and Mexico
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Company

China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease

Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.